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Abstract
Recent studies have identified novel subgroups in ER-negative breast cancer based on the expression pattern of
androgen receptor (AR). One subtype (molecular apocrine) has an over-expression of steroid-response genes and
ErbB2. Using breast cancer cell lines with molecular apocrine features, we demonstrate a functional cross-talk be-
tween AR and ErbB2 pathways. We show that stimulation of AR and ErbB2 pathways leads to the cross-regulation
of gene expression for AR, ErbB2, FOXA1, XBP1, TFF3, and KLK3. As opposed to the physiologic transient phos-
phorylation of extracellular signal–regulated kinase (ERK1/2) observed with the testosterone treatment, we dem-
onstrate that the addition of ErbB2 inhibition leads to a persistent phosphorylation of ERK1/2, which negatively
regulates the downstream signaling and cell growth. This suggests a mechanism for the cross-talk involving
the ERK pathway. Moreover, testosterone stimulates the proliferation of molecular apocrine breast cell lines,
and this effect can be reversed using antiandrogen flutamide and anti-ErbB2 AG825. Conversely, the growth stimu-
latory effect of heregulin can also be inhibited with flutamide, suggesting a cross-talk between the AR and ErbB2
pathways affecting cell proliferation. Importantly, there is a synergy with the combined use of flutamide and AG825
on cell proliferation and apoptosis, which indicates a therapeutic advantage in the combined blockage of AR and
ErbB2 pathways.
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Introduction
Estrogen receptor–negative (ER−) breast cancer constitutes approxi-
mately 30% of all cases and poses a significant management chal-
lenge due to the limited available therapeutic targets. In addition,
the lack of functional ER in breast cancer has been associated with
a more aggressive metastatic phenotype [1]. Therefore, identification
of novel molecular targets in ER− breast cancer can result in more ef-
fective therapies. Using expression microarray analysis, Sorlie et al.
[2,3] have classified breast cancer into luminal, basal, ErbB2-like,
and normal breast–like subtypes. The basal, ErbB2-like, and normal
breast–like subtypes all have a low expression of ER, and ErbB2-like
subtype has an ErbB2 amplification [2,3]. Furthermore, Sotiriou
et al. [4] have demonstrated that ER− breast cancers form a separate
gene expression cluster from ER+ cancers, indicating that they are
two distinct molecular entities.
There is a growing body of evidence suggesting that ER− breast
cancers are heterogeneous with different molecular subtypes. Farmer
et al. [5] have shown that androgen receptor (AR) expression level
divides ER− breast tumors in two major gene expression clusters.
These are ER−/AR− (basal) and ER−/AR+ (molecular apocrine) sub-
types. There is a higher frequency of ErbB2 over-expression (ErbB2+) in
the molecular apocrine subtype [5]. Other studies have confirmed these
findings and demonstrated that the molecular apocrine subtype has a
gene signature similar to that of estrogen response [6,7]. Furthermore,
a cell line model for the molecular apocrine subtype, MDA-MB-453,
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demonstrates an increased proliferation in response to the andro-
gen treatment, which can be reversed using the antiandrogen agent
flutamide [6]. The higher expression of ErbB2 in the molecular apocrine
subtype suggests a biologic significance for the coexpression of ErbB2
and steroid-response genes in this subtype of breast cancer. Interestingly,
in prostate cancer, the ErbB2/ErbB3 pathway regulates AR by stabilizing
AR protein levels and optimizing binding of AR to promoter/enhancer
regions of androgen-regulated genes [8]. Tyrosine phosphorylation of
ErbB2 plays a key role in regulating androgen-mediated proliferation
in prostate cancer, and ErbB2 signaling is required for the optimal tran-
scriptional activity of AR by mechanisms such as tyrosine phosphoryla-
tion of the receptor [9–11]. Furthermore, simultaneous down-regulation
of AR and ErbB2 significantly impairs the survival of prostate cancer
cells [12]. These findings suggest a cross-talk between AR and ErbB2
pathways in prostate cancer.
In this study, we investigate the cross-talk between AR and ErbB2
pathways in breast cancer molecular apocrine subtype and assess the
potential therapeutic implications for our findings.
Materials and Methods
Statistical Analysis
To assess the coexpression of ErbB2 and AR genes, we used the
microarray data from a cohort of 135 breast tumors (ArrayExpress
database accession number: E-UCON-1) [13]. This cohort included
a total of 39 ER− tumors. We normalized the gene-expression ra-
tios for ErbB2 and AR to the mean expression of each gene across
the data.
All statistical analysis was done with the Statistical Package for the
Social Sciences version 14.0 (SPSS Inc., Chicago, IL). Mann–Whitney
U test was applied for the comparison of nonparametric data.
Cell Culture and Treatments
Breast cancer cell linesMDA-MB-453 andMDA-MB-361 were cul-
tured in L15 medium (Invitrogen, Paisley, UK), 10% fetal bovine serum
(FBS). Sum-190 and SK-BR-3 cell lines were cultured in Ham’s F12,
5% FBS and McCoy’s 5a, 10% FBS medium, respectively (Invitro-
gen). BT-474 and prostate cancer cell line LNCaP were grown in
DMEM, 10% FBS and RPMI, 10% FBS, respectively (Invitrogen).
For hormonal and inhibitor experiments, cells were incubated in phe-
nol red–free DMEM (Invitrogen), 10% charcoal-dextran–treated
serum (HyClone, Cramlington, UK).
Testosterone (Sigma, Dorset, UK) treatment was carried out at
100-nM and 1-μM concentrations. Heregulin Beta-1 (Cambridge
Biosciences, Cambridge, UK) was applied at 1-nM concentration. With
the exception of apoptosis assays, flutamide (Sigma) treatment was
done at 10 μM and ErbB2 inhibitor AG825 (Calbiochem, Beeston,
UK) was used at 5-μM concentration. All cells were incubated in phe-
nol red–free media/charcoal-dextran–treated serum 1 day before the
hormonal/inhibitor treatments and medium was changed every 2 days.
Real-time Polymerase Chain Reaction and Western
Blot Analysis
Total RNA extraction from cells lines was performed using TRI
reagent (Sigma). Reverse transcription–polymerase chain reaction
(RT-PCR) to assess the expression levels of AR, ErbB2, FOXA1,
XBP1, TFF3, and KLK3 was performed using gene-specific TaqMan
assays (Applied Biosystems, Foster City, CA). Housekeeping genes
HPRT1 and RPLP0 were used as controls. Experimental procedures
were performed following the manufacturer’s instruction. Relative
gene expressions were calculated as described before [14]. For the cell
treatment experiments: Relative gene expression = gene expression in
the treated group / average gene expression in the control group. All
experiments were performed in four biologic replicates.
Western blots with mouse monoclonal anti-AR antibody (Abcam,
Cambridge, UK) and rabbit polyclonal HER2 antibody (Cell Signal-
ing, Arundel, Australia) were carried out at 1:100 and 1:1000 dilutions
of primary antibody, respectively. Experiments were carried out using
5 μg of each cell lysate. Ponceau staining (Sigma) was carried out as
loading control.
Extracellular Signal–Regulated Kinase Activation
Using ELISA
MDA-MB-453 cells were cultured in 96-well plates to 60% con-
fluence and incubated in phenol red–free media/charcoal-dextran–
treated serum 1 day before the treatments in the following groups:
1) no-treatment control, 2) testosterone (1 μM), and 3) testoster-
one (1 μM) + AG825 (5 μM). Cells were preincubated in DMSO
(groups 1 and 2) or AG825 (group 3) 1 day before the treatments.
Enzyme-linked immunosorbent assay experiments were performed in
two time points: a short incubation at 1 hour and a long incubation
at 18 hours. The amounts of phospho–extracellular signal–regulated
kinase 1/2 (ERK1/2) and total-ERK1/2 proteins were measured
using SuperArray CASE ERK1/2 ELISA kit (Tebu-bio, UK). All
assays were performed in 16 biologic replicates at each time point.
For each experimental group, the ratio of phospho-p65/total-p65
was obtained.
Proliferation Assay
MDA-MB-453 and Sum-190 breast cancer cells were grown in 96-well
plates to 50% confluence. Cells were then treated in the follow-
ings groups for 96 hours with a change of medium at 48 hours: 1)
heregulin, 2) AG825, 3) heregulin + AG825, 4) testosterone, 5) flu-
tamide, 6) testosterone + flutamide, 7) testosterone + AG825, 8) here-
gulin + flutamide, and 9) AG825 + flutamide at the concentrations
described previously. Cells untreated and grown in the same condi-
tions were used as controls. Proliferation was measured using Vybrant
MTT Proliferation Assay Kit (Invitrogen). The percentage of change
in proliferation was calculated relative to the untreated cells at the same
time point. All experiments were performed in 16 biological replicates.
Apoptosis Assays
MDA-MB-453 and Sum-190 cells were grown in six-well plates
on coverslips to 60% confluence. Cells were then incubated in serum-
free medium overnight followed by treatment with flutamide and
AG825 for 18 hours in the following groups: 1) no-treatment con-
trol, 2) flutamide at 10 and 40 μM, 3) AG825 at 5 and 20 μM,
and 4) flutamide + AG825. Hoechst 33258 (Sigma) staining was
performed as described before [15]. Annexin V–fluorescein isothiocya-
nate assay was performed using Annexin V–FITC fluorescence micros-
copy kit (BD Biosciences, Oxford, UK). All experiments were performed
in four biological replicates.
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Results and Discussion
AR and ErbB2 Coexpression in Molecular Apocrine
Breast Cancer
To assess the over-expression of AR and ErbB2 in ER− breast tu-
mors, we analyzed the expression microarray data for these genes in a
cohort of 39 ER− breast tumors [13]. We found that 28% of ER−
tumors were both AR+ and ErbB2+ (Figure 1A). Furthermore, we
noted the 50% of ER− tumors were AR+ and 73% of ErbB2+ cases
were also AR+. These data show that most ER−/ErbB2+ tumors also
over-express AR.
Cell Line Models for AR+/ErbB2+ in ER− Breast Cancer
To identify valid cell line models for the study of cross-talk be-
tween AR and ErbB2 pathways, we assessed the expression of ErbB2
and AR in a number of ER− breast cancer cell lines with known
ErbB2 amplification. We tested ER− cell lines Sum-190, MDA-
MB-453, and SK-BR-3 (Figure 1B). In addition, ER+/ErbB2+ breast
cell lines BT-474 and MDA-MB-361 and prostate cancer cell line
LNCaP were used as ErbB2+ and AR+ controls, respectively. We
found that Sum-190 and MDA-MB-453 cells had over-expression
of both ErbB2 and AR (Figure 1B). However, SK-BR-3 showed
over-expression of only ErbB2 and a low expression of AR (Fig-
ure 1B). This pattern of AR expression in MDA-MB-453 and
SK-BR-3 cell lines has been previously reported [6]. We further con-
firmed the protein expression of AR and ErbB2 in Sum-190 and
MDA-MB-453 cells using Western blot (Figure 1, C and D). These
findings indicate that Sum-190 and MDA-MB-453 cell lines are
AR+/ErbB2+ and provide a valid model for the study of cross-talk
between AR and ErbB2 pathways.
Cross-regulation of Gene Expression between AR and
ErbB2 Pathways
We first assessed the cross-regulation of selected genes between
AR and ErbB2 pathways at the expression level. Expression was mea-
sured at baseline and after modulation of AR pathway with testoster-
one and ErbB2 pathway with heregulin and AG825. Testosterone
treatment for 18 hours significantly increased the ErbB2 expression
Figure 1. AR+/ErbB2+ subtype in estrogen receptor–negative breast cancer. (A) Scatter plot showing the correlation between ErbB2
and AR expression using microarray data from a cohort of 39 ER− breast tumors. Cases with the over-expression of both ErbB2 and AR
are depicted in black. (B) Expression of ErbB2 and AR measured using RT-PCR in Sum-190, MDA-MB-453, SK-BR-3, MDA-MB-361, and
BT-474 breast cancer cell lines (black indicates ER−; red, ER+). LNCaP (blue) is a prostate cancer cell line. Expression is relative to that
of normal breast RNA (Ambion, Warrington, UK). (C) Western blot to show AR protein expression in Sum-190, MDA-MB-453, and LNCaP
cell lines. Ponceau staining is used as loading control. (D) Western blot to show ErbB2 protein expression in Sum-190 and MDA-MB-453
cell lines. Ponceau staining is used as loading control.
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in MDA-MB-453 and Sum-190 cells (P < .01; Figure 2A). In
addition, heregulin significantly increased the ErbB2 expression in
both cell lines and the expression of AR in MDA-MB-453 cells
(P < .01; Figure 2A). We also studied the expression of steroid-
response genes FOXA1, XBP1, and TFF3 [6] and the AR signaling
marker KLK3 [gene for prostate-specific antigen (PSA) protein]. We
observed a significant induction in the expression of FOXA1 and
XBP1 with both testosterone and heregulin treatments in Sum-190
cells (P < .01; Figure 2B). Furthermore, in MDA-MB-453 cells, the
expression of both TFF3 and KLK3 was significantly increased after
testosterone treatment for 18 hours (P < .01), and this was inhibited
using AG825 (Figure 2, C and D). We confirmed that AG825 at
5 μM inhibits the phosphorylation of ErbB2 using ELISA (data
not shown). It is notable that testosterone was used at two con-
centrations of 100 nM and 1 μM, and we observed similar results
with these concentrations. Moreover, testosterone did not stimulate
TFF3 and KLK3 expression in Sum-190 cells. Interestingly, we ob-
served a down-regulation of AR with the testosterone treatment in
MDA-MB-453 cells (Figure 2A). This finding has been previously
reported in other cancer cell lines such as LNCaP and is due to
Figure 2. Cross-regulation of gene expression between AR and ErbB2 pathways. (A) Relative expression of AR and ErbB2 using RT-PCR
in MDA-MB-453 and Sum-190 cell lines after treatments with testosterone and heregulin. Expression is relative to that of untreated cells.
(B) Relative expression of FOXA1 and XBP1 using RT-PCR in Sum-190 cell line after treatments with testosterone and heregulin. Expres-
sion is relative to that of untreated cells. (C) Relative expression of TFF3 in the MDA-MB-453 cell line after treatments with testosterone
(TES) and TES + AG825. (D) Expression change of KLK3 shown as −ΔCT in the MDA-MB-453 cell line after treatment with testosterone
(TES) and TES + AG825. −ΔCT = [−(CT (KLK3) − CT (housekeeping genes)] was applied because there is no baseline expression of KLK3
in the MDA-MB-453 cell line. All data are shown for testosterone at a 1 μM concentration.
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the transcriptional regulation of AR by testosterone [16]. These find-
ings indicate that there is a cross-regulation in the expression of se-
lected genes between AR and ErbB2 pathways.
ErbB2 Inhibition Leads to a Persistent ERK Phosphorylation
By Testosterone
There is available data regarding a similar cross-talk between AR
and ErbB2 in prostate cancer. A suggested mechanism for this cross-
talk is ErbB2-mediated activation of AR through the ERK in prostate
cancer [17,18]. In addition, ERK itself is a target of AR activation
[17,19]. In view of these, we studied the role of the ERK pathway
as a possible mechanism for the AR-ErbB2 cross-talk in MDA-MB-
453 cells. The activation of ERK pathway was measured using
ELISA (see Materials and Methods section). We observed that testos-
terone, as previously been reported [20], transiently increased the
phosphorylation of ERK1/2 after a short incubation at 1 hour
(P < .01), and this effect disappeared after a longer incubation at
18 hours (Figure 3A). However, when cells were treated with a com-
bination of testosterone and ErbB2 inhibitor AG825, we found that
the increase in ERK1/2-phosphorylation was not only present at
1 hour but also persisted after 18 hours of incubation (P < .01;
Figure 3A). Similar results were obtained with testosterone treatment
at 100 nM and 1 μM concentrations. It has been shown that a phys-
iologic response to testosterone involves a transient phosphorylation
of ERK and persistent ERK phosphorylation, down-regulates cAMP
response element–binding protein activity, leading to the inhibition
of both cAMP response element–mediated gene expression and cell
growth [20]. Furthermore, a novel inhibitor PM-20, which induces
persistent phosphorylation of ERK1/2, has a growth-inhibitory effect
on a number of cancer cell lines including hepatoma and breast can-
cer [21]. In view of these findings, we suggest a model for the AR-
ErbB2 cross-talk in which ErbB2 activity is required for a physiologic
transient phosphorylation of ERK1/2 by testosterone, and ErbB2
inhibition leads to a sustained testosterone-induced ERK1/2 phos-
phorylation resulting in the inhibition of downstream signaling and
cell proliferation (Figure 3B). It is notable that we did not find a
cross-talk at the phosphorylation steps of AR and ErbB2 (data not
shown). However, it is still possible that the cross-talk exists at more
than one level between AR and ErbB2 pathways.
The Cross-talk between AR and ErbB2 Affects Proliferation
and Apoptosis
We next investigated the effect of cross-talk between AR and
ErbB2 pathways on cell proliferation and apoptosis. Using MTT
assay, we measured the proliferation of MDA-MB-453 and Sum-
190 cells after treatments with testosterone, heregulin, AG825, and
flutamide. Testosterone stimulated cell proliferation in both lines
(P < .01; Figure 4, A and B), and this effect was blocked using anti-
androgen flutamide and ErbB2 inhibitor AG825 (Figure 4, A and B).
In addition, heregulin enhanced proliferation in MDA-MB-453 cells
(P < .01), which was also reversed using AG825 and flutamide
(Figure 4A). Furthermore, the combination of AG825 and flutamide
showed a significant synergy against cell proliferation in both lines
(P < .01; Figure 4, A and B). These findings suggest a therapeutic
advantage in combined blockage of AR and ErbB2 pathways. We
also investigated the effect of combined inhibition of AR and ErbB2
on apoptosis. Flutamide and AG825 were applied at different con-
centrations and apoptosis was assessed using Hoechst and Annexin V
assays. We observed a significant additive effect in the proapoptotic
response to flutamide at 40 μM and AG825 at 20 μM (P < .03;
Figure 4, C and D). This effect was also present in the lower con-
centrations of these inhibitors (data not shown). These data suggest
a cross-talk between AR and ErbB2 pathways affecting cell prolif-
eration and apoptosis which has potential therapeutic implications
in the molecular apocrine subtype of breast cancer. Interestingly, a
similar observation in prostate cancer has revealed that simultaneous
down-regulation of AR and ErbB2 pathways significantly impairs the
survival of prostate cancer cells [12]. Future studies are needed to
Figure 3. AR-ErbB2 cross-talk and ERK1/2 activation. (A) The relative ratio of phospho-ERK1/2/total-ERK1/2 using ELISA in MDA-MB-453
cell line. No Tx indicates no treatment; TES, testosterone at 1 μM; AG, AG825 at 5 μM. Cells were incubated for 1 hour (short incubation)
and 18 hours (long incubation). *P < .01 is compared with the untreated cells using Mann–Whitney U test. (B) Schematic model for the
cross-talk between AR and ErbB2 in molecular apocrine subtype of breast cancer. TES indicates testosterone; p-ERK1/2, phosphory-
lated ERK1/2; arrow, stimulatory effect; crossed line, inhibitory effect.
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examine the clinical implications of these findings in the manage-
ment of molecular apocrine breast cancer.
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